CJC-1295 + Ipamorelin 5 mg + 5 mgPackung mit 10 Vials6 auf Lager22 % sparen
Empfohlenpeptideintermediate6 auf Lager

CJC-1295 + Ipamorelin 5 mg + 5 mg

Klassische GHRH- + Ghrelin-Mimetikum-Kombination

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

Dosis
5mg + 5mg / Vial
Form
Lyophilisiertes Pulver
Packung
Packung mit 10 Vials

Ausschließlich für Forschungszwecke. Diese Verbindung wird ausschließlich für In-vitro-Forschung und Laborzwecke verkauft und ist nicht für den menschlichen Verzehr oder therapeutische Anwendung bestimmt. Mit dem Kauf bestätigen Sie, dass Sie ein qualifizierter Forscher sind, und stimmen unserem vollständigen Haftungsausschluss zu.

186 € EUR
22 % sparen
Packung mit 10 Vials
Statt 238 € EUR
Als Packung mit 10 Vials verkauft

Nur noch 6 Packungen

🧪Laborverifiziert
✓Durch Dritte geprüft
⚡Schneller weltweiter Versand
🔒Sichere Kartenzahlung
Überblick

Kombiniertes Forschungsvial, das das GHRH-Analogon CJC-1295 mit dem selektiven Ghrelin-Mimetikum Ipamorelin paart. Die am häufigsten untersuchte GH-Sekretagog-Kombination mit Doppelmechanismus in der Peptidforschung.

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

Mechanismus

CJC-1295 unterstützt die basale GHRH-Rezeptorsignalisierung, während Ipamorelin selektive Ghrelinrezeptor-Pulse antreibt. Die Forschung legt synergistische, naturalistische GH-Freisetzungsmuster in Studienprobanden nahe.

Laborbericht

HPLC-verifiziert gegen eine Reinheitsspezifikation von ≥99 %. Unabhängig geprüft von akkreditierten Drittlaboren.

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

FAQ für Forschende

CJC-1295 + Ipamorelin — häufige Fragen

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

Weiterführende Lektüre

Leitfäden zu CJC-1295 + Ipamorelin

Verwandte Verbindungen

Forschende entdecken auch